Alkermes Names Joshua Reed Chief Financial Officer

Alkermes appointed Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept. 15, 2025. Reed will report to Richard Pops, Chief Executive Officer of Alkermes, and will join the company’s management committee.

Reed brings over 30 years of financial leadership experience, with a strong focus in the biotechnology and pharmaceutical sectors. He currently serves on the board of directors of Scholar Rock Holding Corporation

Most recently, he served as CFO of Omega Therapeutics; before that, he was the CFO at Aldeyra Therapeutics. Earlier in his career, Reed spent over a decade at Bristol Myers Squibb, culminating in his role as Vice President and Head of Finance Operations for the U.S. and Puerto Rico. 

His experience also includes roles at JPMorganChase, Credit Suisse First Boston, and Chase Manhattan Bank.

Pops said, “Joshua brings a wealth of financial expertise and strategic insight from his extensive experience in the biopharmaceutical industry. We gain his financial acumen and dedication to excellence as we continue to focus on driving strong performance across our commercial business, advancing our pipeline, and delivering long-term shareholder value.”

“I’m delighted to be joining Alkermes and look forward to working with Richard and the team to build on Alkermes’ strong financial foundation and advance its strategic priorities with a financial strategy that supports continued innovation, operational excellence and long-term growth,” said Reed.